View Post

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Alice Melão From: The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …

View Post

First come, first served: Novartis finalizes CAR-T application, claims priority review

In In The News by Barbara Jacoby

By: Juliet Preston From: MedCity News Novartis has made good on its promise to submit a biologics license application (BLA) for its lead CAR-T candidate in the first quarter of the fiscal year. With two days to spare, no less. According to a statement released on Wednesday, the FDA has accepted the submission and granted Novartis a priority review. That …